Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 598-603 , November 2009

Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

  • Hideaki Miyake, M.D., Ph.D.

      Affiliations

    • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-78-382-6155; fax: +81-78-382-6169
    • ,
  • Toshifumi Kurahashi, M.D., Ph.D.

      Affiliations

    • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Atsushi Takenaka, M.D., Ph.D.

      Affiliations

    • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Taka-aki Inoue, M.D., Ph.D.

      Affiliations

    • Department of Urology, Hyogo Cancer Center, Akashi, Japan
    • ,
  • Masato Fujisawa, M.D., Ph.D.

      Affiliations

    • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan

Received 10 April 2008 ,Revised 17 July 2008 ,Accepted 22 July 2008.

References 

  1. Figlin RA. Renal cell carcinoma: Management of advanced disease. J Urol. 1999;161:381–387
  2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408–417
  3. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463
  4. Bellmunt J, Montagut C, Albiol S, et al. Present strategies in the treatment of metastatic renal cell carcinoma: An update on molecular targeting agents. BJU Int. 2007;99:274–280
  5. Lane BR, Rini BI, Novick AC, et al. Targeted molecular therapy for renal cell carcinoma. Urology. 2007;69:3–10
  6. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–550
  7. Akaza H, Tsukamoto T, Murai M, et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2007;37:755–762
  8. Miyake H, Hara I, Sakai I, et al. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: A preliminary report. Int J Clin Oncol. 2005;10:338–341
  9. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2005;20:289–296
  10. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  11. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  12. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie N Engl J Med. 1998;338:1272–1278
  13. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132
  14. McDermott DF, Regan MM, Clark JI, et al. Randomized Phase III trial of high-dose interleukin-2 vs. subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–141
  15. Atzpodien J, Hoffmann R, Franzke M, et al. Thirteen-year, long-term efficacy of interferon-α and interleukin-2 based home therapy in patients with advanced renal cell carcinoma. Cancer. 2002;95:1045–1050
  16. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584–5592
  17. Verra N, Jansen R, Groenewegen G, et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-αa in patients with progressive metastatic renal cell carcinoma. Br J Cancer. 2003;88:1346–1351
  18. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92:2286–2296
  19. Clark JI, Gaynor ER, Martone B, et al. Daily subcutaneous ultra-low-dose interleukin-2 with daily low-dose interferon-α in patients with advanced renal cell carcinoma. Clin Cancer Res. 1999;5:2374–2380
  20. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52–55

PII: S1078-1439(08)00180-4

doi: 10.1016/j.urolonc.2008.07.023

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 598-603 , November 2009

Article Tools

* Image Usage & Resolution